^
Association details:
Biomarker:No biomarker
Cancer:Lung Non-Squamous Non-Small Cell Cancer
Regimen:GemVin (gemcitabine + vinorelbine tartrate)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
09/15/2020
Excerpt:
For patients with metastatic nonsquamous NSCLC and PS 0 and 1 who have contradictions to immunotherapy, the panel decided that the following chemotherapy regimens are "useful in certain circumstances" including 1) carboplatin with paclitaxel (or albumin-bound paclitaxel), docetaxel, etoposide, gemcitabine, or pemetrexed; all are category 1; 2) cisplatin with paclitaxel (or albumin-bound paclitaxel), docetaxel, etoposide, gemcitabine, or pemetrexed; all are category 1; 3) bevacizumab with carboplatin and either paclitaxel or pemetrexed; and 4) gemcitabine with either docetaxel or vinorelbine.